IDH1 and cholangiocarcinoma: Since the initial discovery of IDH mutations in cancer in 2008, recurrent somatic mutations in IDH1 and IDH2 have been identified in different malignancies, including gliomas, thyroid carcinomas, cholangiocarcinomas, sarcomas, and AML [122].